Tag: IgA nephropathy
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9bn in strategic expansion
In a major development in the biotechnology industry, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN) have announced a definitive agreement ... Read More
Novartis to expand renal portfolio with Chinook Therapeutics acquisition
Novartis has announced its agreement to acquire Chinook Therapeutics, a clinical stage biopharmaceutical company based in Seattle, Washington in a deal worth up to around ... Read More
Chinook Therapeutics gets orphan drug status from EC for atrasentan in IgAN
Chinook Therapeutics, a US-based biopharma company, has secured orphan drug designation for atrasentan from the European Commission (EC) for the treatment of primary IgA nephropathy ... Read More
Calliditas initiates NEFIGARD trial to study Nefecon in Berger’s disease
Nefecon phase 3 trial : Calliditas Therapeutics has initiated a phase 3 clinical trial called NEFIGARD to evaluate its lead candidate Nefecon for the treatment ... Read More